Dear Pharma Pals,

In the evolving world of pharmaceutical and drug delivery sciences, complex injectables have emerged as critical enablers of modern therapy. These advanced parenteral systems go far beyond simple aqueous or oil-based solutions, offering targeted, sustained, and controlled drug release, improved bioavailability, and increased therapeutic precision. As the pharmaceutical industry shifts toward treating chronic diseases, cancers, and autoimmune disorders with biologics, peptides, and nanoparticle-based agents, complex injectables are becoming essential.

Complex injectables hold tremendous promise – but they are also among the most technically challenging dosage forms to develop, characterize, manufacture, and scale. The exclusive article in this issue by Dr. Govind S Pandey explores the key scientific principles behind complex injectables, the hurdles they face across the product lifecycle, and the growing global market shaping their adoption.

Did you know that drugs and biologics have the highest (68.5%) import actions among all FDA regulated commodities in 2023? Dr. Binh Nguyen, a retired USFDA officer and founder and CEO of Wynngate Consulting, in his in-depth article discusses the ongoing quality issues in the bio/pharmaceutical industry and offers solutions aimed at advancing quality and stabilizing the drug supply chain to ensure the delivery of high-quality products to patients.

Also read the exclusive coverage of PDA India Chapter Annual Meeting 2025 focused on the themes of globalization, modernization, and transformation in pharmaceutical manufacturing.

Harjit Singh Dhaul
Publisher & Editor